Polygenic Scores (PGS): A Complete Guide to the Future of Predictive Genomics
For decades, scientists have known that our DNA influences health. Yet most common diseases, like diabetes, depression, and heart disease, do not stem…
-
-
APGxA Thought Leader Interview Series:Wafaa M Rashed, BPharm. MSc., PhD, Founder of PAPERI
“Africa must lead in developing pharmacogenomic algorithms and AI models that are trained on African genomic data.” – Dr. Wafaa M. Rashed (PAPERI)…
-
APGxA Thought Leader Interview Series: Dr. Maria Pashayan, PharmD, PhD, Pharmacogenomics Consultant
“We need to do better. As we know, adverse drug reactions are the fourth leading cause of death in the United States. So,…
-
APGxA Interview Series: Dr. Jayden Lee, PharmD, EMBA – Co-founder and chief genomics officer, UGenome AI
Chief Genomics Officer @ UGenome AI, Dr. Jayden Lee makes genomic medicine personal and accessible for everyone, ensuring that “jayden lee” leads innovation.
-
Should You Build or Partner? A Strategic Guide for PGx Startups Targeting Clinical Markets
The pharmacogenomics (PGx) market is heating up, with new entrants popping up around the globe—especially in North America, Europe, and parts of Africa and Asia.
-
10 Pharmacogenomics Startups to Watch in 2025
Pharmacogenomics (PGx) is entering a new phase of growth. What began as a niche offering in clinical genetics is now becoming a critical…
-
Dr. Faisal A Islam, Medical Education (PGx) – Interview Series
Pharmacogenomics education faces a unique challenge: the science is advancing rapidly, but awareness and understanding among both patients and providers lag far behind….
-
Are Prescribers Aware of the Liability Associated With Ignoring PGx FDA Recommendations for Commonly Used Medications?
Dr. Patricia Cammazola doesn’t think so. “Physicians/prescribers are often not aware of the liability associated with not considering PGx FDA recommendations and CPIC…
-
Dr. Patricia Camazzola, Pharmacogenomics Consultant & RxOptimization Founder – Interview Series
With decades of clinical experience under her belt, Dr. Camazzola has emerged as a key voice in helping health systems, physicians, and patients integrate pharmacogenomics into routine care. Her mission is clear: to close the gap between evidence-based PGx guidelines and how medicine is practiced daily.
-
Guarding Against Chemotherapy Toxicity: The Promise of Helix’s DPYD Test
The key lies in the DPYD gene, which produces an enzyme called DPD that helps the body break down and clear fluoropyrimidines.
End of content
End of content